Blinatumomab: An Investigational BiTE Antibody Construct Designed to Direct the Body’s Cell-destroying T-Cells Against Target Cells Expressing CD19 – Emerging Insight and Market Forecast to 2030 – ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Blinatumomab - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Blinatumomab is an investigational BiTE antibody construct designed to direct the body's cell-destroying T cells against target cells expressing CD19, a protein found on the surface of B-cell derived leukemias and lymphomas. Blinatumomab is the first of the BiTE antibody constructs and Amgen has received orphan drug designation from the FDA for th

Click to view original post